--- title: "TransThera Sciences Added to Major Hang Seng Indexes, Exits Small-Cap Gauge" type: "News" locale: "en" url: "https://longbridge.com/en/news/278380204.md" description: "TransThera Sciences (Nanjing), Inc. has been added to multiple Hang Seng Index Series benchmarks, including large- and mid-cap indices, effective March 9, 2026. The company will exit the Hang Seng Composite SmallCap Index, indicating increased investor recognition and a shift towards larger-cap segments. This reclassification may enhance its visibility and attract more institutional investment. TransThera focuses on innovative drug development in the biotech sector and aims to access both mainland China and international capital markets." datetime: "2026-03-09T11:12:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278380204.md) - [en](https://longbridge.com/en/news/278380204.md) - [zh-HK](https://longbridge.com/zh-HK/news/278380204.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278380204.md) | [繁體中文](https://longbridge.com/zh-HK/news/278380204.md) # TransThera Sciences Added to Major Hang Seng Indexes, Exits Small-Cap Gauge ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential An announcement from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available. TransThera Sciences (Nanjing), Inc. has been selected as a constituent of multiple Hang Seng Index Series benchmarks, including several large- and mid-cap, Stock Connect, mainland China companies, and a dedicated biotech index, effective March 9, 2026. The company will simultaneously be removed from the Hang Seng Composite SmallCap Index, a move the board interprets as evidence of rising investor recognition and a shift in its market profile toward larger-cap and more widely tracked segments, potentially broadening its investor base and liquidity. The index inclusions span key factor-based and dividend-focused indices, as well as the Hang Seng Stock Connect Hong Kong and Biotech 50 gauges, reinforcing TransThera’s visibility among both generalist and specialist healthcare investors. This reclassification may enhance the company’s standing in the Hong Kong market by aligning it with larger, more investable peers and facilitating increased participation from passive and institutional funds that follow these benchmarks. **More about TransThera Sciences (Nanjing). Inc.** TransThera Sciences (Nanjing), Inc. is a biopharmaceutical company listed in Hong Kong that focuses on innovative drug development, with a particular emphasis on biotech-related therapeutics. The group targets both mainland China and international capital markets, positioning itself within the broader biotech segment accessible via Stock Connect indices. **Average Trading Volume:** 1,931,371 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** HK$27.95B For an in-depth examination of 2617 stock, go to TipRanks’ Overview page. ### Related Stocks - [Dacheng Hang Seng Technology ETF(QDII) (159740.CN)](https://longbridge.com/en/quote/159740.CN.md) - [Fullgoal CSI Hugangshen Innovative Drugs Industry ETF (159748.CN)](https://longbridge.com/en/quote/159748.CN.md) - [TRACKER FUND (02800.HK)](https://longbridge.com/en/quote/02800.HK.md) - [HSTECH ETF (03032.HK)](https://longbridge.com/en/quote/03032.HK.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md) - [China Southern Hang Seng ETF (513600.CN)](https://longbridge.com/en/quote/513600.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md) - [ISHARESHSI (03115.HK)](https://longbridge.com/en/quote/03115.HK.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md) - [ChinaAMC Hang Seng Technology ETF(QDII) (513180.CN)](https://longbridge.com/en/quote/513180.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md) - [Hang Seng TECH ETF I (159742.CN)](https://longbridge.com/en/quote/159742.CN.md) - [Huatai-PB CSOP Hang Seng Technology ETF(QDII) (513130.CN)](https://longbridge.com/en/quote/513130.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md) - [ChinaAMC Hang Seng ETF (159920.CN)](https://longbridge.com/en/quote/159920.CN.md) - [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/en/quote/520500.CN.md) - [Tianhong Hang Seng TECH ETF(QDII) (520920.CN)](https://longbridge.com/en/quote/520920.CN.md) - [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/en/quote/159570.CN.md) - [Hang Seng Index (00HSI.HK)](https://longbridge.com/en/quote/00HSI.HK.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md) - [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/en/quote/562050.CN.md) - [CSOP HSI ETF (03037.HK)](https://longbridge.com/en/quote/03037.HK.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md) - [China Southern Hang Seng ETF Feeder Fund-A (501302.CN)](https://longbridge.com/en/quote/501302.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md) ## Related News & Research - [Hong Kong Completes First Green Methanol Bunkering, Driving Green Transformation of Its International Shipping Hub](https://longbridge.com/en/news/278049602.md) - [China five-year plan: China will 'seize the commanding heights of science and tech development'](https://longbridge.com/en/news/277878204.md) - [Hong Kong considers raising MPF contributions after 13-year freeze on thresholds](https://longbridge.com/en/news/278254329.md) - [Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China](https://longbridge.com/en/news/278445287.md) - [06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis](https://longbridge.com/en/news/278376120.md)